This Article Full Text Full Text (PDF) All Versions of this Article: theoncologist.2008-0089v1 13/9/954    most recent eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Zhou, X. Articles by Qin, X. Search for Related Content PubMed PubMed Citation Articles by Zhou, X. Articles by Qin, X.

Lymphoma

The Role of Complement in the Mechanism of Action of Rituximab for B-Cell Lymphoma: Implications for Therapy

^aChangzheng Hospital, Second Military Medical University, Shanghai, China; ^bDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; ^cHarvard Medical School, Laboratory for Translational Research, Cambridge, Massachusetts, USA

Key Words. Rituximab • CD20 • Mechanism • Resistance • Complement • B-cell non-Hodgkin's lymphoma

Correspondence: Xuebin Qin, M.D., Ph.D., Harvard Medical School, One Kendall Square, Building 600, 3rd Floor, Cambridge, Massachusetts 02139, USA. Telephone: 617-621-6102; Fax: 617-621-6148; e-mail: xuebin_qin{at}hms.harvard.edu

Received April 9, 2008; accepted for publication August 5, 2008; first published online in THE ONCOLOGIST Express on September 8, 2008.

Disclosure: The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the authors, planners, independent peer reviewers, or staff managers.

Rituximab, a genetically engineered chimeric monoclonal antibody specifically binding to CD20, was the first antibody approved by the U.S. Food and Drug Administration for the treatment of cancer. Rituximab significantly improves treatment outcome in relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL). However, there are also some challenges for us to overcome: why 50% of patients are unresponsive to rituximab in spite of the expression of CD20, and why some responsive patients develop resistance to further treatment. Although the antitumor mechanisms of rituximab are not completely understood, several distinct antitumor activities of rituximab have been suspected, including complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), apoptosis, and direct growth arrest. To counteract resistance to rituximab therapy, several strategies have been developed to: (a) augment the CDC effect by increasing CD20 expression, heteroconjugating rituximab to cobra venom factor and C3b, and inhibiting membrane complement regulatory protein, especially CD59, function; (b) enhance the ADCC effect through some immunomodulatory cytokines and CR3-binding β-glucan; and (c) reduce the apoptotic threshold or induce apoptotic signaling on the tumor. Extensive studies indicate that rituximab combined with these approaches is more effective than a single rituximab approach. Herein, the mechanism of action of and resistance to rituximab therapy in B-cell NHL, in particular, the involvement of the complement system, are extensively reviewed.